CA2373706A1 - Fibrin sealants providing less inflammatory response and methods using same - Google Patents
Fibrin sealants providing less inflammatory response and methods using same Download PDFInfo
- Publication number
- CA2373706A1 CA2373706A1 CA002373706A CA2373706A CA2373706A1 CA 2373706 A1 CA2373706 A1 CA 2373706A1 CA 002373706 A CA002373706 A CA 002373706A CA 2373706 A CA2373706 A CA 2373706A CA 2373706 A1 CA2373706 A1 CA 2373706A1
- Authority
- CA
- Canada
- Prior art keywords
- fibrin
- sealant
- sealants
- adhesion
- inflammatory response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000565 sealant Substances 0.000 title claims abstract description 112
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims abstract description 110
- 229950003499 fibrin Drugs 0.000 title claims abstract description 100
- 108010073385 Fibrin Proteins 0.000 title claims abstract description 99
- 102000009123 Fibrin Human genes 0.000 title claims abstract description 99
- 238000000034 method Methods 0.000 title claims abstract description 52
- 230000028709 inflammatory response Effects 0.000 title claims abstract description 21
- 208000031737 Tissue Adhesions Diseases 0.000 claims abstract description 49
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 44
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 97
- 229920000642 polymer Polymers 0.000 claims description 35
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 102000016359 Fibronectins Human genes 0.000 claims description 10
- 108010067306 Fibronectins Proteins 0.000 claims description 10
- 101800000974 Fibrinopeptide A Proteins 0.000 claims description 9
- JWICNZAGYSIBAR-LEEGLKINSA-N (4s)-4-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-[[2-[[(2s)-3-carboxy-1-[[(2s)-1-[[1-[[(2s)-1-[[(2s)-4-carboxy-1-[[2-[[2-[[2-[[(2s)-1-[[(1s)-1-carboxy-4-(diaminomethylideneamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)N)CC1=CC=CC=C1 JWICNZAGYSIBAR-LEEGLKINSA-N 0.000 claims description 8
- 102400000525 Fibrinopeptide A Human genes 0.000 claims description 8
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 229940072107 ascorbate Drugs 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 abstract description 16
- 230000023597 hemostasis Effects 0.000 abstract description 8
- 230000029663 wound healing Effects 0.000 abstract description 7
- 239000012530 fluid Substances 0.000 abstract description 6
- 238000007789 sealing Methods 0.000 abstract description 6
- 230000017423 tissue regeneration Effects 0.000 abstract description 4
- 238000012377 drug delivery Methods 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 description 31
- 241001465754 Metazoa Species 0.000 description 26
- 108090000190 Thrombin Proteins 0.000 description 23
- 239000000178 monomer Substances 0.000 description 23
- 229960004072 thrombin Drugs 0.000 description 23
- 230000009467 reduction Effects 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 208000014674 injury Diseases 0.000 description 17
- 210000002435 tendon Anatomy 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 16
- 238000001356 surgical procedure Methods 0.000 description 16
- 206010052428 Wound Diseases 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 241000252983 Caecum Species 0.000 description 13
- 210000004534 cecum Anatomy 0.000 description 13
- 210000001072 colon Anatomy 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 13
- 108010073651 fibrinmonomer Proteins 0.000 description 11
- 108010049003 Fibrinogen Proteins 0.000 description 10
- 102000008946 Fibrinogen Human genes 0.000 description 10
- 229940012952 fibrinogen Drugs 0.000 description 10
- 208000035874 Excoriation Diseases 0.000 description 9
- 238000005299 abrasion Methods 0.000 description 9
- 238000002350 laparotomy Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 210000004303 peritoneum Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 102000004506 Blood Proteins Human genes 0.000 description 5
- 108010017384 Blood Proteins Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003447 ipsilateral effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 238000000611 regression analysis Methods 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000001949 anaesthesia Methods 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 238000002224 dissection Methods 0.000 description 4
- UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 3
- 208000032984 Intraoperative Complications Diseases 0.000 description 3
- -1 NSAIDS Substances 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 208000002847 Surgical Wound Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 229960002210 batroxobin Drugs 0.000 description 3
- 239000012503 blood component Substances 0.000 description 3
- 229960003260 chlorhexidine Drugs 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 2
- 108090000935 Antithrombin III Proteins 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 108010071289 Factor XIII Proteins 0.000 description 2
- 101800003778 Fibrinopeptide B Proteins 0.000 description 2
- 241000489861 Maximus Species 0.000 description 2
- 241000581002 Murex Species 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 239000004792 Prolene Substances 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229960005348 antithrombin iii Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940012444 factor xiii Drugs 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000009101 premedication Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 239000004627 regenerated cellulose Substances 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000566113 Branta sandvicensis Species 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920004937 Dexon® Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 102400001063 Fibrinopeptide B Human genes 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 206010034650 Peritoneal adhesions Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 108010063086 avidin-agarose Proteins 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000002729 catgut Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 229960004207 fentanyl citrate Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- MYRIFIVQGRMHRF-OECXYHNASA-N fibrinopeptide b Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)CNC(=O)[C@@H]1CCC(=O)N1 MYRIFIVQGRMHRF-OECXYHNASA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- IRYFCWPNDIUQOW-UHFFFAOYSA-N fluanisone Chemical compound COC1=CC=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 IRYFCWPNDIUQOW-UHFFFAOYSA-N 0.000 description 1
- 229960005220 fluanisone Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000002683 hand surgery Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000000954 inflammatory inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 229940127216 oral anticoagulant drug Drugs 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 108010091612 threonine drug combination neomycin glycine cysteine bacitracin Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229960004175 xylazine hydrochloride Drugs 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/046—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13690399P | 1999-06-01 | 1999-06-01 | |
| US60/136,903 | 1999-06-01 | ||
| PCT/US2000/015139 WO2000072856A1 (en) | 1999-06-01 | 2000-06-01 | Fibrin sealants providing less inflammatory response and methods using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2373706A1 true CA2373706A1 (en) | 2000-12-07 |
Family
ID=22474935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002373706A Abandoned CA2373706A1 (en) | 1999-06-01 | 2000-06-01 | Fibrin sealants providing less inflammatory response and methods using same |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1223955A1 (enrdf_load_stackoverflow) |
| JP (1) | JP2003500171A (enrdf_load_stackoverflow) |
| AU (1) | AU771328B2 (enrdf_load_stackoverflow) |
| CA (1) | CA2373706A1 (enrdf_load_stackoverflow) |
| NO (1) | NO20015760L (enrdf_load_stackoverflow) |
| NZ (1) | NZ515581A (enrdf_load_stackoverflow) |
| WO (1) | WO2000072856A1 (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8414907B2 (en) | 2005-04-28 | 2013-04-09 | Warsaw Orthopedic, Inc. | Coatings on medical implants to guide soft tissue healing |
| US9119901B2 (en) | 2005-04-28 | 2015-09-01 | Warsaw Orthopedic, Inc. | Surface treatments for promoting selective tissue attachment to medical impants |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5230996A (en) * | 1990-06-04 | 1993-07-27 | Therapy 2000 | Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation |
| US5278189A (en) * | 1990-06-04 | 1994-01-11 | Rath Matthias W | Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A) |
| US5462990A (en) * | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| SE9101853D0 (sv) * | 1991-06-17 | 1991-06-17 | Jonas Wadstroem | Improved tissue ashesive |
| DE69229004D1 (de) * | 1991-11-07 | 1999-05-27 | Univ Southern California | Zusammensetzungen und verfahren zur verhinderung der adhäsionbildung |
| CN1091315A (zh) * | 1992-10-08 | 1994-08-31 | E·R·斯奎布父子公司 | 血纤维蛋白封闭剂组合物及其使用方法 |
-
2000
- 2000-06-01 NZ NZ515581A patent/NZ515581A/xx unknown
- 2000-06-01 EP EP00938042A patent/EP1223955A1/en not_active Withdrawn
- 2000-06-01 CA CA002373706A patent/CA2373706A1/en not_active Abandoned
- 2000-06-01 JP JP2000620966A patent/JP2003500171A/ja active Pending
- 2000-06-01 AU AU53134/00A patent/AU771328B2/en not_active Ceased
- 2000-06-01 WO PCT/US2000/015139 patent/WO2000072856A1/en active IP Right Grant
-
2001
- 2001-11-26 NO NO20015760A patent/NO20015760L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1223955A1 (en) | 2002-07-24 |
| WO2000072856A1 (en) | 2000-12-07 |
| NZ515581A (en) | 2004-01-30 |
| JP2003500171A (ja) | 2003-01-07 |
| AU5313400A (en) | 2000-12-18 |
| AU771328B2 (en) | 2004-03-18 |
| WO2000072856A9 (en) | 2002-04-18 |
| NO20015760D0 (no) | 2001-11-26 |
| NO20015760L (no) | 2002-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU771557B2 (en) | Prevention of post surgical adhesions using a fibrin monomer sealant | |
| AU697045B2 (en) | Self-supporting sheet-like material of cross-linked fibrin for preventing post- operative adhesions | |
| AU2004206150B2 (en) | Hemostatic materials | |
| Cole et al. | A pilot study evaluating the efficacy of a fully acetylated poly-N-acetyl glucosamine membrane formulation as a topical hemostatic agent | |
| US20100256671A1 (en) | Tissue sealant for use in noncompressible hemorrhage | |
| IL157095A (en) | A carrier containing solid fibrinogen and solid thrombin | |
| CN109529098A (zh) | 一种外科医用粘合剂 | |
| KR101786786B1 (ko) | 개선된 피브린 밀봉 방법 | |
| US8367802B2 (en) | Method to produce fibrin monomer in acid media for use as tissue sealant | |
| US6558687B2 (en) | Fibrin polymer structure | |
| AU771328B2 (en) | Fibrin sealants providing less inflammatory response and methods using same | |
| Bhatia | Traumatic injuries | |
| Bhatia | Adhesive Biomaterials for Tissue Repair and Reconstruction | |
| Davis et al. | The strength of microvascular anastomoses—an experimental evaluation in rats | |
| KR20240151476A (ko) | 지혈용 재료 | |
| Bhatia | Adhesives: Tissue Repair and Reconstruction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20090601 |